Peptide · Vial
Verified recordBPC 157
$9010mg
An experimental peptide best known for early research into tissue repair, tendon injury and wound response.
Current batchBPC 004-012
Published result99.2% reported purity
EternaGen / KPV 003-026Peptide · Research use only
KPV
$75CAD
A three-amino-acid peptide fragment explored in early inflammation, immune-signalling and gut models.
Purchasing review required
Select strength
1
Can’t find the right record?Send support the product name or batch code.
Contact supportProduct information
KPV, clearly explained.
A three-amino-acid peptide fragment explored in early inflammation, immune-signalling and gut models.
Overview
Most KPV research comes from laboratory systems and mouse models of intestinal inflammation. Human benefit and safety have not been established, and regulators report little to no human exposure data for administered KPV products.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Published research focuses on inflammatory signalling in cells and experimental colitis in mice.- Format
- Vial
- Available strengths
- 10mg
- Batch
- KPV 003-026
- Purity
- 99.1%
Research at a glanceCell and animal evidence; administered human-drug evidence absent
Reviewed 23 July 2026View research context Specifications
Product details
- Sequence / identity
- Lys-Pro-Val
- Molecular formula
- Confirm in batch record
- Molecular weight
- 342.44 g/mol
- Storage and handling
- Store and handle according to the verified batch record.
Batch documentationVerified record available
Review the analytical record connected to this exact batch.
- Batch
- KPV 003-026
- Purity
- 99.1%
Important research-use boundary
Health Canada lists the named compound or components among unauthorized injectable drugs identified in the Canadian market. A research-use label does not make an unauthorized product suitable or legal for personal use.
Explore the research
What has been studied?
Keep the context attached
Check what was studied, what researchers observed, and the limitation attached to each finding.
Question 01
Intestinal inflammation models
Murine colitis studies report changes in histology, inflammatory markers and recovery under experimental conditions.
Evidence so far: Animal evidenceQuestion 02
Epithelial inflammatory signalling
Human-derived cell-line studies examine NF-κB signalling, chemokine secretion and cellular uptake.
Evidence so far: In-vitro mechanistic evidenceQuestion 03
Human administration
FDA reports no identified human exposure data for drug products containing KPV.
Evidence so far: Direct human evidence gapProposed mechanism
How researchers are investigating the mechanism.
Cell studies report effects on NF-κB-related signalling and cytokine release. Intestinal models also examine uptake through the PepT1 transporter. These findings describe experimental pathways, not established clinical outcomes.
Study records
What was studied—and what was not.
See what researchers tested, what they observed and the limitation attached to each result.
Study 01Two mouse models of inflammatory bowel disease
- What researchers saw
- Investigators reported reduced inflammatory measures and earlier recovery in KPV-treated animals.
- Why that is not the whole story
- Animal colitis models cannot establish human efficacy, dose, route or safety.
Study 02Immortalized human bronchial epithelial cell experiments
- What researchers saw
- The study reported inhibition of NF-κB-related signalling and chemokine secretion.
- Why that is not the whole story
- A cell-line mechanism is not a clinical respiratory or anti-inflammatory outcome.
Evidence gaps
What remains unknown?
- No adequately controlled human efficacy or safety trials were identified.
- Human pharmacokinetics, route-specific tolerability and immunogenicity remain uncharacterized.
- Cell and mouse findings cannot support a personalized treatment or dosing protocol.
Primary sources
Check the original sources.
- Primary animal studyKannengiesser et al. KPV in murine inflammatory-bowel-disease models. Inflamm Bowel Dis. 2008. PMID 18092346.
- Primary cell studyLand. KPV and inflammatory signalling in human bronchial epithelial cells. Pulm Pharmacol Ther. 2012. PMID 22837805.
- Regulatory safety reviewU.S. FDA. KPV bulk-substance safety considerations.
Related products
Continue comparing.
Peptide · Vial
Verified recordGHK-CU
From CA$5550mg100mg
A naturally occurring copper-binding peptide explored in skin, collagen and wound-healing research.
Current batchGHK 006-031
Published result99.5% reported purity
Peptide · Pen
Verified recordMOTS-c
From CA$20010mg40mg
A peptide made inside mitochondria and studied for its connection to energy, exercise and metabolic stress.
Current batchMOTS 005-021
Published result99.0% reported purity